CoChat

5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft

Open access
Borodovsky, Alexandra, Salmasi, Vafi, Turcan, Sevin, Fabius, Armida W. M., Baia, Gilson S., Eberhart, Charles G., Weingart, Jon D., Gallia, Gary L., Baylin, Stephen B., Chan, Timothy A., Riggins, Gregory J. · 2013 · Oncotarget
Cited by 156

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

// Alexandra Borodovsky 1 , Vafi Salmasi 1 , Sevin Turcan 2 , Armida W. M. Fabius 2 ,Gilson S. Baia 1 , Charles G. Eberhart 3 , Jon D. Weingart 1,4 , Gary L. Gallia 1,4 , Stephen B. Baylin 4 , Timothy A. Chan 2 , and Gregory J. Riggins 1,4 1 Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA 2 Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA 3 Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA 4 Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA Correspondence: Gregory J. Riggins, email: // Keywords : IDH, 5-azacytidine, progressive glioma, xenograft, astrocytoma, methylation Received : September 12, 2013 Accepted : September 16, 2013 Published : September 16, 2013 Abstract Somatic mutations in Isocitrate Dehydrogenase 1 ( IDH1 ) are frequent in low grade and progressive gliomas and are characterized by the production of 2-hydroxyglutarate (2-HG) from α-ketoglutarate by the mutant enzyme. 2-HG is an “oncometabolite” that competitively inhibits α-KG dependent dioxygenases resulting in various widespread cellular changes including abnormal hypermethylation of genomic DNA and suppression of cellular differentiation. Despite the growing understanding of IDH mutant gliomas, the development of effective therapies has proved challenging in part due to the scarcity of endogenous mutant in vivo models. Here we report the generation of an endogenous IDH1 anaplastic astrocytoma model which rapidly grows in vivo, produces 2-HG and exhibits DNA hypermethylation. Using this model, we have demonstrated the preclinical efficacy and mechanism of action of the FDA approved demethylating drug 5-azacytidine in vivo . Long term administration of 5-azacytidine resulted in reduction of DNA methylation of promoter loci, induction of glial differentiation, reduction of cell proliferation and a significant reduction in tumor growth. Tumor regression was observed at 14 weeks and subsequently showed no signs of re-growth at 7 weeks despite discontinuation of therapy. These results have implications for clinical trials of demethylating agents for patients with IDH mutated gliomas.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.1408

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

Metadata

Authors
Borodovsky, A., Salmasi, V., Turcan, S., Fabius, A. W. M., Baia, G. S., Eberhart, C. G., Weingart, J. D., Gallia, G. L., Baylin, S. B., Chan, T. A., & Riggins, G. J.
Venue
Oncotarget
Published
2013-09-16
Volume
4
Issue
10
Pages
1737-1747
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2126665584
Cited by
156
References
14
FWCI
7.10
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.